Migraine is a highly prevalent neurological pain syndrome, and its management is 
limited due to side effects posed by current preventive therapies. Calcitonin 
gene-related peptide (CGRP) plays a crucial role in the pathogenesis of 
migraine. In recent years, research has been dedicated to the development of 
monoclonal antibodies against CGRP and CGRP receptors for the treatment of 
migraine. This review will focus on the first US FDA-approved CGRP-receptor 
monoclonal antibody developed for the prevention of migraine: erenumab. Two 
Phase II trials (one for episodic migraine and one for chronic migraine) and two 
Phase III trials for episodic migraine have been published demonstrating the 
efficacy and safety of erenumab in the prevention of migraine.